NCT06618495View on ClinicalTrials.gov

Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 13, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2026

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)

Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.

Trial Locations (1)

100091

Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China, Beijing

All Listed Sponsors
lead

Xiyuan Hospital of China Academy of Chinese Medical Sciences

OTHER